Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;51(4):242-248.
doi: 10.5045/br.2016.51.4.242. Epub 2016 Dec 23.

Therapy-related myeloid neoplasms in children and adolescents

Hee Won Cho  1 , Young Bae Choi  2 , Eun Sang Yi  1 , Ji Won Lee  1 , Ki Woong Sung  1 , Hong Hoe Koo  1 , Keon Hee Yoo  3
Affiliations

Therapy-related myeloid neoplasms in children and adolescents

Hee Won Cho et al. Blood Res. 2016 Dec.

Abstract

Background: This retrospective study aimed to characterize and analyze the outcome of therapy-related myeloid neoplasms (t-MNs) in children and adolescents.

Methods: The medical records of 16 patients under 21 years of age at the time of t-MN diagnosis were reviewed.

Results: The median patient age was 11.5 years (range, 1.6-20.4 yr). Twelve patients had therapy-related acute myeloid leukemia, 3 patients had myelodysplastic syndrome, and 1 patient had chronic myelomonocytic leukemia. The median latency period was 29 months (range, 11-68 mo). Fourteen patients had cytogenetic aberrations, 8 of whom had an 11q23 abnormality. Of the 13 patients treated with curative intent, 12 patients received myeloid-type induction therapy that led to complete remission (CR) in 8 patients. Nine patients underwent allogeneic transplantation; 4 patients did not undergo transplantation due to chemotherapy-related toxic death (N=3) or parental refusal (N=1). The 5-year overall survival and event-free survival of the 13 patients treated with a curative intent were 46.2% and 30.8%, respectively. For the 9 patients who underwent allogeneic transplantation, the 5-year event-free survival was 66.7%.

Conclusion: A significant proportion of young patients with t-MNs can experience long-term survival, and allogeneic transplantation plays a key role for attaining cure in these patients.

Keywords: Allogeneic hematopoietic stem cell transplantation; Pediatric population; Therapy-related myeloid neoplasms.

PubMed Disclaimer

Conflict of interest statement

Authors' Disclosures of Potential Conflicts of Interest: No potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1
Fig. 1. Overall survival (OS) and event-free survival (EFS) for 13 patients who were treated with a curative intent. The 5-year OS was 46.2%, and the 5-year EFS was 30.8%.
Fig. 2
Fig. 2. Overall survival (OS) and event-free survival (EFS) for 9 patients who underwent allogeneic hematopoietic stem cell transplantation. The 5-year OS was 66.7% and the 5-year EFS was 66.7%.
Fig. 3
Fig. 3. The event-free survival (EFS) after allogeneic hematopoietic stem cell transplantation in terms of disease status at the time of transplantation. The 5-year EFS rate was not significantly different between CR1/CR2 (N=5) and persistent disease status (N=4) (P=0.478).
Abbreviations: CR1, complete remission 1; CR2, complete remission 2.
See this image and copyright information in PMC

References

    1. Ng AK, Travis LB. Subsequent malignant neoplasms in cancer survivors. Cancer J. 2008;14:429–434. - PubMed
    1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951. - PubMed
    1. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43–52. - PubMed
    1. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35:418–429. - PMC - PubMed
    1. Larson RA. Therapy-related myeloid neoplasms. Haematologica. 2009;94:454–459. - PMC - PubMed

LinkOut - more resources